BioNTech SE (BNTX) Net Income towards Common Stockholders (2018 - 2026)

BioNTech SE has reported Net Income towards Common Stockholders for 8 years, with the latest figure at -$174.4 million in Q4 2025.

• Quarterly Net Income towards Common Stockholders fell 147.59% year-over-year to -$174.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$1.1 billion (down 41.52% YoY) and the FY2025 annual result came in at -$1.3 billion, down 80.55% from the prior year.
• Net Income towards Common Stockholders slipped to -$174.4 million in Q4 2025 per BNTX's latest filing, from $91.3 million in the prior quarter.
• Over five years, Net Income towards Common Stockholders peaked at $7.2 billion in Q3 2021 and troughed at -$865.6 million in Q2 2024.
• A 5-year average of $1.7 billion and a median of $343.3 million in 2024 frame the typical range for Net Income towards Common Stockholders.
• The sharpest annual moves came in 2021 and 2025: Net Income towards Common Stockholders surged 1512953662792.27% in 2021, then sank 147.59% in 2025.
• Over 5 years, Net Income towards Common Stockholders stood at $3622.0 in 2021, then surged by 114544050.96% to $4.1 billion in 2022, then tumbled by 77.48% to $934.5 million in 2023, then plunged by 60.79% to $366.4 million in 2024, then tumbled by 147.59% to -$174.4 million in 2025.
• According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered -$174.4 million, $91.3 million, and -$474.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.